Viagra Regulatory Status: US, EU, Canada, and UK

How Sildenafil Works: The PDE5 Mechanism

Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. Sexual stimulation triggers nitric oxide release from endothelial cells and nerve terminals, which activates guanylate cyclase to produce cGMP. That second messenger relaxes smooth muscle, allowing arterial inflow and trabecular engorgement. Sildenafil does not initiate erection on its own. It amplifies the nitric oxide/cGMP signal that sexual arousal provides 1.

The selectivity profile matters for safety. Sildenafil has roughly 10-fold selectivity for PDE5 over PDE6 (a retinal enzyme), which explains the transient blue-tinted vision some users report at higher doses. Its selectivity over PDE3 (a cardiac isoform) exceeds 4,000-fold, a ratio that contributed to the FDA's confidence in cardiovascular safety during the original review 2. Peak plasma concentration occurs at approximately 60 minutes after oral dosing, with a terminal half-life of 3 to 5 hours. The drug is metabolized primarily by CYP3A4, with a minor contribution from CYP2C9 3.

United States: FDA Approval and Prescription-Only Status

The FDA approved sildenafil citrate (Viagra) on March 27, 1998, making it the first oral therapy for erectile dysfunction 3. Approval rested on data from 21 randomized, double-blind, placebo-controlled trials enrolling over 3,000 men. The key publication by Goldstein et al. in the New England Journal of Medicine reported that 69% of all attempts at intercourse were successful on sildenafil 50 mg and 100 mg versus 22% on placebo (P<0.001) across 532 men with ED of organic, psychogenic, or mixed etiology 1.

Sildenafil remains Schedule IV prescription-only under US federal law. No petition for OTC reclassification has been submitted to the FDA. The primary regulatory concern is the absolute contraindication with organic nitrates. Concurrent use can produce severe, potentially fatal hypotension, and the FDA's position is that a prescriber must screen for nitrate use before dispensing 3.

Generic sildenafil entered the US market in December 2017 after Teva Pharmaceutical Industries reached a patent settlement with Pfizer. By 2020, generic prescriptions represented over 90% of sildenafil dispensing volume, and the average cash price for a 30-tablet supply of sildenafil 100 mg dropped below $30 at major retail pharmacies 4. Pfizer separately launched its own authorized generic through Greenstone LLC at a reduced price point.

The FDA also approved sildenafil 20 mg under the brand name Revatio in 2005 for pulmonary arterial hypertension (PAH), an indication with separate dosing, labeling, and NDA 5. The two NDAs carry different therapeutic claims, but the active molecule is identical.

European Union: Centralized EMA Authorization

The European Medicines Agency (EMA) granted centralized marketing authorization for Viagra on September 14, 1998, six months after the FDA 6. This centralized procedure made the approval valid across all EU member states simultaneously, avoiding the need for country-by-country submissions.

The Committee for Medicinal Products for Human Use (CHMP) reviewed the same key dataset submitted to the FDA. Its European Public Assessment Report (EPAR) noted "clinically meaningful improvement in erectile function" across subpopulations including diabetes and post-prostatectomy patients 6.

Pfizer's Supplementary Protection Certificate (SPC) for sildenafil in the EU expired in June 2013, four years before the US patent expiry. Generic competition in Europe arrived correspondingly earlier. By 2014, over a dozen generic sildenafil products held EMA or national-level authorizations. Pricing in several EU markets fell below €1 per tablet for the 100 mg dose.

Prescription requirements vary by member state under the EU's subsidiarity principle for pharmacy regulation, but sildenafil for ED remains prescription-only throughout the EU-27. No member state has reclassified it for pharmacy sale as of May 2026. The EMA has noted that "the benefit-risk balance remains favorable" in each five-year renewal assessment, most recently in 2023 6.

United Kingdom: The First Major Market to Approve OTC Access

The UK's regulatory path diverged significantly from the rest of the world in 2017. The Medicines and Healthcare products Regulatory Agency (MHRA) reclassified sildenafil 50 mg from prescription-only medicine (POM) to pharmacy medicine (P) on November 28, 2017. The product launched in spring 2018 under the brand name Viagra Connect 7.

This was a global first for a PDE5 inhibitor. The MHRA's decision rested on a specific risk-management framework:

Only the 50 mg strength was reclassified. The 25 mg and 100 mg tablets remain prescription-only. Pharmacists must complete a structured checklist before each sale. The checklist screens for nitrate use, recent stroke or myocardial infarction (within six months), severe hepatic impairment, hypotension (systolic blood pressure <90 mmHg), and concurrent use of potent CYP3A4 inhibitors such as ritonavir or ketoconazole 7.

Men purchasing Viagra Connect must be 18 or older and must confirm they have previously been diagnosed with ED. The pharmacist can decline the sale if clinical red flags emerge during the consultation. Post-market surveillance data from the first two years of OTC availability showed no signal of increased adverse events compared to the prescription-era baseline 8.

Dr. Michael Wilks, former Chair of the British Medical Association's Ethics Committee, described the move as "a pragmatic recognition that many men were already obtaining sildenafil from unregulated online sources, and a supervised pharmacy sale is far safer than an anonymous internet purchase."

The Royal Pharmaceutical Society supported the reclassification, publishing guidance for community pharmacists on conducting the structured assessment. Sales volume data from the Pharmaceutical Services Negotiating Committee indicated that over 500,000 packs of Viagra Connect were sold in UK pharmacies during the first 12 months.

Canada: Health Canada Approval and Generic Market

Health Canada approved sildenafil (Viagra) on March 23, 1999, roughly one year after the FDA 9. The drug received a Notice of Compliance under the Food and Drugs Act and was classified as a prescription medication under Schedule I.

Canada's generic sildenafil market opened in 2013 following patent expiry. Teva Canada, Apotex, and several other manufacturers launched competing products. The Pan-Canadian Pharmaceutical Alliance (pCPA) negotiated public formulary pricing that brought per-tablet costs below CAD $2 for the 100 mg dose.

Provincial formulary coverage for sildenafil varies. Ontario and Quebec do not list sildenafil on their public drug benefit plans for ED. British Columbia covers it with Special Authority approval if the patient has documented ED secondary to radical prostatectomy, diabetes, or spinal cord injury 10. Alberta's formulary excludes it entirely for ED but covers the 20 mg PAH indication.

Unlike the UK, Health Canada has not received or evaluated any application for OTC reclassification of sildenafil. The Canadian Pharmacists Association has not publicly advocated for such a switch. Sildenafil remains firmly prescription-only across all provinces and territories.

Global Trends: Where OTC Access May Expand

New Zealand became the second country to permit OTC sildenafil sales in 2014 when Medsafe reclassified sildenafil 50 mg as a pharmacist-only medicine. Poland followed with a similar reclassification in 2021 11. Australia's Therapeutic Goods Administration (TGA) reclassified sildenafil 50 mg to pharmacist-only (Schedule 3) status in February 2023, with pharmacy sales beginning in early 2024.

These reclassifications share common design elements. All restrict OTC access to a single strength (50 mg). All require a structured pharmacist consultation at the point of sale. All exclude patients taking nitrates, alpha-blockers at high doses, or potent CYP3A4 inhibitors. The emerging model is what regulators call "behind-the-counter" access: not a free shelf product, but a pharmacist-mediated supply without a physician prescription 11.

Whether the FDA or EU will follow remains uncertain. A 2022 citizen petition to the FDA requesting sildenafil OTC reclassification was denied on the grounds that the nitrate interaction requires professional medical assessment. The FDA's response stated that "the current prescription-only status adequately ensures that the necessary screening occurs prior to use" 4.

Safety Signals That Shaped Regulation

Post-marketing surveillance has identified several safety concerns that regulatory agencies reference when evaluating sildenafil's prescription status. The most clinically significant is the nitrate interaction. Between 1998 and 2002, the FDA received 1,473 reports of serious cardiovascular events in sildenafil users, including 522 deaths 12. Subsequent analysis by Mittleman et al. published in the Journal of the American College of Cardiology found that the absolute risk of myocardial infarction was not elevated in sildenafil users who did not take nitrates, confirming that the drug itself is not cardiotoxic but that the drug-nitrate combination is dangerous 12.

A second concern emerged in 2007 when the FDA added a warning about sudden sensorineural hearing loss (SSNHL) to the sildenafil label. Post-marketing reports identified 29 cases across all PDE5 inhibitors. The association remains unproven but the precautionary labeling persists 3.

Non-arteritic anterior ischemic optic neuropathy (NAION) is the third flagged signal. The FDA updated labeling in 2005 to note post-marketing reports of NAION in PDE5 inhibitor users. A retrospective cohort study by Campbell et al. found an adjusted hazard ratio of 1.02 (95% CI 0.92 to 1.12), suggesting no statistically significant increase in NAION risk 13. The warning remains on the label as a precaution, but no regulatory agency has restricted access on this basis.

These safety findings collectively support the current regulatory consensus: sildenafil is safe for the general ED population when nitrate co-administration is excluded, but the nitrate screen is considered mandatory by most agencies.

Sildenafil for Pulmonary Arterial Hypertension: A Separate Regulatory Track

Sildenafil's approval for PAH followed a distinct development program. The SUPER-1 trial (N=278) demonstrated that sildenafil 20 mg three times daily improved six-minute walk distance by 45 meters compared to placebo (P<0.001) in patients with WHO functional class II-III PAH 14. The FDA approved Revatio in June 2005, and the EMA followed in October 2005.

The PAH indication is approved in the US, EU, UK, and Canada. It carries a different dosing schedule (20 mg three times daily rather than on-demand), a different brand name, and in most markets a separate formulary listing. Generic sildenafil 20 mg for PAH is available in all four jurisdictions and is included on the WHO Model List of Essential Medicines 15.

How Prescribing Frameworks Differ Across Jurisdictions

The practical experience of obtaining sildenafil varies substantially by country, even where the prescription-only classification is identical. In the United States, prescriptions can be written by physicians, nurse practitioners, and physician assistants. Telehealth prescribing is permitted in all 50 states for sildenafil, and multiple direct-to-consumer platforms offer asynchronous consultations with same-day electronic prescribing.

The EU permits physician prescribing universally, but nurse and pharmacist prescribing authority varies by member state. In France, sildenafil prescriptions from a general practitioner are valid for 12 months. In Germany, each prescription is limited to a single dispensing episode, requiring a new consultation for refills.

Canada permits physician and nurse practitioner prescribing. Provincial pharmacy regulations in Alberta, British Columbia, and Ontario now authorize pharmacist prescribing for selected conditions, and some provinces have added ED to the pharmacist-prescribable list, though uptake has been limited.

The UK offers the broadest access spectrum. A patient can obtain sildenafil via GP prescription (any strength), private prescription, online prescriber, or direct pharmacy purchase of Viagra Connect 50 mg without any prescription. The UK's four-pathway model is the most permissive regulatory framework for sildenafil access among high-income nations.

Patients taking organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) must not use sildenafil regardless of jurisdiction. This absolute contraindication is consistent across all four regulatory agencies and is the single most important screening item in any prescribing or dispensing interaction 3.